Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Modeling Software

September 15, 2011 12:02 pm | Product Releases | Comments

Accelrys, Inc.’s Discovery Studio life sciences modeling and simulation software predicts protein-protein aggregation.

TOPICS:

GE Healthcare Invests $1 Billion in Oncology Solutions

September 15, 2011 9:31 am | News | Comments

GE Healthcare plans to dedicate $1 billion over the next five years to expand its advanced cancer diagnostic and molecular imaging capabilities.

TOPICS:

Positive Results for Hemophilia Drug, Factor VIIa-CTP

September 15, 2011 9:29 am | News | Comments

Prolor Biotech, Inc.  reported positive results from a comparative study of its biobetter longer-acting version of the hemophilia drug Factor VIIa (Factor VIIa-CTP) in hemophilic mice.

TOPICS:
Advertisement

Daiichi Sankyo, AstraZeneca Launch Nexium Capsules

September 15, 2011 9:25 am | News | Comments

Daiichi Sankyo Co., Ltd. and AstraZeneca KK announced the launch of Nexium Capsule (esomeprazole magnesium) 10mg and Nexium Capsule 20mg in Japan following the NHI (National Health Insurance) drug price listing received on September 12, 2011.

TOPICS:

Nucleofection Unit

September 15, 2011 9:21 am | Product Releases | Comments

Lonza’s 4D-Nucleofector Y unit enables adherent nucleofection of neural cells grown in 24-well tissue culture plates. For transfection, disposable conductive polymer 24-well dipping electrode arrays are inserted into the culture plate.

TOPICS:

Cryopreserved CD8+ T-cells and CD19+ B-cells

September 15, 2011 9:17 am | Product Releases | Comments

SeraCare Life Sciences’ Cryo-T8 Human CD8+ T-cells and Cryo-B Human CD19+ B-cells include a range of donor demographics and related HLA information

TOPICS:

Synthetic DNA Replaces the Original in Yeast Cells

September 15, 2011 8:41 am | News | Comments

Scientists at Johns Hopkins University School of Medicine have replaced the DNA in the arm of a yeast chromosome with computer-designed, synthetically produced DNA that is structurally distinct from its original DNA to produce a healthy yeast cell.

TOPICS:

Unfolding the Mystery Behind Protein Folding

September 15, 2011 8:33 am | News | Comments

An Oak Ridge National Laboratory invention able to predict three-dimensional structures of protein could impact drug discovery and human health.

TOPICS:
Advertisement

Mouse Genetic Blueprint Discovered

September 15, 2011 8:15 am | News | Comments

Researchers have developed a mouse genetic blueprint that may explain human genetics. Led by researchers at the Wellcome Trust Sanger Institute and the University of Oxford, the international team decoded and compared the genome sequence of 17 mouse strains.

TOPICS:

Agilent Grant Supports Large Proteins Studies

September 15, 2011 8:08 am | News | Comments

Agilent Technologies Inc. and the Agilent Technologies Foundation announced that professor Gerhard Wagner, Harvard Medical School, has received an Agilent Thought Leader Award in support of his work using high-magnetic-field nuclear magnetic resonance (NMR) spectroscopy to analyze large proteins.

TOPICS:

NIH, NanoBio Combine for Intranasal RSV Vaccine

September 14, 2011 12:33 pm | News | Comments

NanoBio Corporation announced a licensing agreement with the National Institutes of Health in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections.

TOPICS:

Nanobiotix Starts Clinical Trial on NBTXR3

September 14, 2011 12:29 pm | News | Comments

Nanobiotix announced that its lead compound NBTXR3 received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.

TOPICS:

MorphoSys Partners With Bayer for Cancer Antibody Program

September 14, 2011 12:27 pm | News | Comments

MorphoSys AG announced that Bayer HealthCare Pharmaceuticals initiated a Phase 1 clinical trial with the HuCAL-derived antibody-drug conjugate, BAY 94-9343, in the therapeutic area of oncology.

TOPICS:

Avila Completes First Cohort Dosing of AVL-292 Study

September 14, 2011 12:20 pm | News | Comments

Avila Therapeutics Inc. completed 28 days of dosing of the first cohort of patients in its Phase 1b clinical trial of AVL-292 and is advancing to the second dose cohort in this trial.

TOPICS:

One-Third of All Clinical Trial Changes Are Avoidable

September 14, 2011 12:12 pm | News | Comments

Nearly 60% of all protocols used in clinical trials for new drugs are amended during the trial.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading